Addison Capital Co Has $990,000 Position in Teva Pharmaceutical Industries Ltd (TEVA)

Addison Capital Co lessened its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 7.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,219 shares of the company’s stock after selling 4,455 shares during the period. Addison Capital Co’s holdings in Teva Pharmaceutical Industries were worth $990,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $106,000. Bank of Nova Scotia increased its holdings in shares of Teva Pharmaceutical Industries by 8.3% in the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock worth $229,000 after purchasing an additional 528 shares in the last quarter. Penserra Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $129,000. Americafirst Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth $303,000. Finally, Salem Investment Counselors Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the 2nd quarter. Salem Investment Counselors Inc. now owns 9,400 shares of the company’s stock worth $312,000 after purchasing an additional 1,068 shares in the last quarter. 51.96% of the stock is owned by institutional investors.

TEVA has been the subject of a number of research analyst reports. BTIG Research lifted their target price on Teva Pharmaceutical Industries to $20.00 in a report on Friday, December 15th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, October 25th. Goldman Sachs Group upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Friday, December 15th. Finally, Citigroup upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Thursday, January 4th. Eight analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $21.32.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded down $0.01 during midday trading on Friday, reaching $20.70. The company had a trading volume of 21,430,000 shares, compared to its average volume of 26,730,000. The stock has a market capitalization of $20,630.00, a P/E ratio of -3.53, a PEG ratio of 1.53 and a beta of 0.54. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a 12 month low of $10.85 and a 12 month high of $37.94.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 2nd. The company reported $0.95 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd will post 3.72 earnings per share for the current fiscal year.

WARNING: This story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3146387/addison-capital-co-has-990000-position-in-teva-pharmaceutical-industries-ltd-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.